Dr. Abraham Morgentaler

But I was still worried about high levels of testosterone. And I'll tell you how, can I tell you how that? Yeah, yeah, go ahead. No, no, I'm enjoying this. This is also amazing. It's sort of funny how these things happen, right? So I had a fellow from Brazil, Hernani Rodin, and he had pulled together a lot of research data for us. We published some.

But I was still worried about high levels of testosterone. And I'll tell you how, can I tell you how that? Yeah, yeah, go ahead. No, no, I'm enjoying this. This is also amazing. It's sort of funny how these things happen, right? So I had a fellow from Brazil, Hernani Rodin, and he had pulled together a lot of research data for us. We published some.

But I was still worried about high levels of testosterone. And I'll tell you how, can I tell you how that? Yeah, yeah, go ahead. No, no, I'm enjoying this. This is also amazing. It's sort of funny how these things happen, right? So I had a fellow from Brazil, Hernani Rodin, and he had pulled together a lot of research data for us. We published some.

And the New England Journal of Medicine had published maybe the biggest paper of this century in 2002, which was the Women's Health Initiative, which was about hormone replacement therapy in women. It was the largest placebo-controlled trial at the time. It was something like over 20,000 individuals.

And the New England Journal of Medicine had published maybe the biggest paper of this century in 2002, which was the Women's Health Initiative, which was about hormone replacement therapy in women. It was the largest placebo-controlled trial at the time. It was something like over 20,000 individuals.

And the New England Journal of Medicine had published maybe the biggest paper of this century in 2002, which was the Women's Health Initiative, which was about hormone replacement therapy in women. It was the largest placebo-controlled trial at the time. It was something like over 20,000 individuals.

And everybody at that time had thought that hormones in women were great, protective about all these things. And the headline from the 2002 paper in women was that HRT, hormone replacement therapy in women, was actually associated with increased risks, increased. And it really affected that field.

And everybody at that time had thought that hormones in women were great, protective about all these things. And the headline from the 2002 paper in women was that HRT, hormone replacement therapy in women, was actually associated with increased risks, increased. And it really affected that field.

And everybody at that time had thought that hormones in women were great, protective about all these things. And the headline from the 2002 paper in women was that HRT, hormone replacement therapy in women, was actually associated with increased risks, increased. And it really affected that field.

Today, you know, there's lots of follow-up studies from that, and it's clear the scare stories from those initial headlines weren't true. But in 2003, as testosterone was just becoming more popular, We contacted New England Journal and we said, are you interested in a review paper on testosterone? They said, yes, we're interested in a paper on risks.

Today, you know, there's lots of follow-up studies from that, and it's clear the scare stories from those initial headlines weren't true. But in 2003, as testosterone was just becoming more popular, We contacted New England Journal and we said, are you interested in a review paper on testosterone? They said, yes, we're interested in a paper on risks.

Today, you know, there's lots of follow-up studies from that, and it's clear the scare stories from those initial headlines weren't true. But in 2003, as testosterone was just becoming more popular, We contacted New England Journal and we said, are you interested in a review paper on testosterone? They said, yes, we're interested in a paper on risks.

So we worked with them and we pulled together all the papers we could find on testosterone and prostate cancer. And one day our nanny comes to me and we've divided up the papers and he's a very confident person. Confident man. And now he's a very prominent urologist in Porto Alegre in Brazil. And he looks nervous. I'd never seen him nervous before.

So we worked with them and we pulled together all the papers we could find on testosterone and prostate cancer. And one day our nanny comes to me and we've divided up the papers and he's a very confident person. Confident man. And now he's a very prominent urologist in Porto Alegre in Brazil. And he looks nervous. I'd never seen him nervous before.

So we worked with them and we pulled together all the papers we could find on testosterone and prostate cancer. And one day our nanny comes to me and we've divided up the papers and he's a very confident person. Confident man. And now he's a very prominent urologist in Porto Alegre in Brazil. And he looks nervous. I'd never seen him nervous before.

And he says, Chief, do you have the papers that show that high testosterone is dangerous for prostate cancer? And I said, no, Nanny, I thought you must have them. And what we found and published was that we couldn't find one single article that showed any good evidence that high levels of testosterone or testosterone therapy were associated with anything bad with prostate cancer.

And he says, Chief, do you have the papers that show that high testosterone is dangerous for prostate cancer? And I said, no, Nanny, I thought you must have them. And what we found and published was that we couldn't find one single article that showed any good evidence that high levels of testosterone or testosterone therapy were associated with anything bad with prostate cancer.

And he says, Chief, do you have the papers that show that high testosterone is dangerous for prostate cancer? And I said, no, Nanny, I thought you must have them. And what we found and published was that we couldn't find one single article that showed any good evidence that high levels of testosterone or testosterone therapy were associated with anything bad with prostate cancer.

Higher prevalence, higher stage, the higher mortality, nothing. And we were shocked. The editors at New England Journal were also shocked. And I was relatively young. This is more than 20 years ago. And they were uncomfortable publishing the paper. So they sent it first to three urologists who gave it high scores. But they didn't believe this thing about the prostate cancer.

Higher prevalence, higher stage, the higher mortality, nothing. And we were shocked. The editors at New England Journal were also shocked. And I was relatively young. This is more than 20 years ago. And they were uncomfortable publishing the paper. So they sent it first to three urologists who gave it high scores. But they didn't believe this thing about the prostate cancer.